Updated
Medicus PharmaMDCX · Healthcare
$1.87+2.19%
Market cap$113M
IndustryDrug Manufacturers - General
Medicus Pharma (MDCX) Financial statements
Net income was -$47M.
Key figures
The diluted share count rose 397% over the period (dilution).
- Revenue, FY2025
- —
- Net income
- -$47M+323.8% on 2024
- Operating margin
- —
- Free cash flow
- —
Financial statements
Fiscal 2023–2025.
Medicus Pharma income statement, fiscal 2023–2025
| USD | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Research and development | $193,578 | $4M | $8M |
| Selling, general and admin | $5M | $8M | $18M |
| Operating income | -$5M | -$11M | -$34M |
| Interest expense | — | — | $197,382 |
| Pre-tax income | -$5M | -$11M | -$35M |
| Income tax | $0 | $0 | $0 |
| Net income | -$5M | -$11M | -$47M |
| EPS (diluted) | -$76.50 | -$58.00 | -$137.00 |
| Diluted shares | 0M | 0M | 0M |
Medicus Pharma balance sheet, fiscal 2023–2025
| USD | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash and short-term investments | $2M | $4M | $9M |
| Total current assets | $2M | $5M | $10M |
| Total assets | $2M | $6M | $10M |
| Total current liabilities | $781,609 | $2M | $10M |
| Long-term debt | $0 | — | $0 |
| Total liabilities | $781,609 | $3M | $10M |
| Shareholders' equity | $1M | $3M | -$67,554 |
| Net debt | -$2M | -$4M | -$3M |
Medicus Pharma cash flow, fiscal 2023–2025
| USD | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$4M | -$10M | -$23M |
| Stock-based compensation | $98,585 | $713,119 | $2M |
| Net borrowing | — | $0 | $4M |
From Medicus Pharma's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.